Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 5, 2011, Pages 549-553

  Fabroni, C ^a   Gori, A ^a   Troiano, M ^a   Prignano, F ^a   Lotti, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

infliximab; nail; NAPSI; psoriasis; treatment

Indexed keywords

CALCIPOTRIOL; ETRETIN; INFLIXIMAB; TAZAROTENE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; NAIL DISEASE; NAIL PSORIASIS; NAIL PSORIASIS SEVERITY INDEX; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RATING SCALE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NAIL DISEASES; PSORIASIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79954622167     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03826.x     Document Type: Article

References (13)

1. Scher RK,. Psoriasis of the nail. Dermatol Clin 1985; 3: 387-394. (Pubitemid 15017620)
2. Nevitt GJ, Hutchinson PE,. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 1996; 135: 533-537. (Pubitemid 26340262)
3. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblended, nonrandomized, open-label study. Br J Dermatol 2008; 159: 453-456. (Pubitemid 352009870)
4. Lawry M,. Biological therapy and nail psoriasis. Dermatol Ther 2007; 20: 60-67. (Pubitemid 46568378)
5. Hussain W, Coulson L, Owen C,. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008; 33: 500-522.
6. Reich K, Nestle F, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
7. Pathirana D, Ormerod AD, Saiag P, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol, Oct 2009; 23 0: 5-70.
8. Rich P, Griffiths C, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol, Feb 2008; 58 0: 224-231.
9. Rich P, Scher RK,. Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212. (Pubitemid 36951265)
10. Bianchi L, Bergamin A, De Felice C, Capriotti E, Chimenti S,. Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005; 52 0: 736-737. (Pubitemid 40585474)
11. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM,. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009; 61: 233-239.
12. McGonagle D,. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. JEADV 2009; 23 0: 9-13.
13. Olivieri I, D'Angelo S, Palazzi C, Padula A,. Treatment strategies for early psoriatic arthritis. Expert Opin Pharmacother 2009; 10 0: 271-282.